A Phase 1 Study of BMS-833923 (XL139) in Subjects With Advanced or Metastatic Cancer
Status:
Completed
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety of BMS-833923 (XL139) in patients with
advanced or metastatic cancers and determine the recommended phase 2 dose range and schedule